The
global Cell Therapy Market size is expected to reach USD
20.07 billion by 2030, expanding at a CAGR of 22.66% from 2024 to 2030,
according to a new report by Grand View Research, Inc. The market players are
witnessing an increasing interest in the development of advanced therapies that
are based on tissue, genes, or cells. Research communities and companies
continue to make large investments in the culturing and isolation of a broad
range of cell types, such as keratinocytes, chondrocytes, cartilage, stem,
dermal papilla, & epithelial cells for the development of novel therapies.
Regulatory
authorities such as FDA play a crucial role in the growth of the market by
undertaking initiatives related to the development and approval of advanced
treatment development as well as restriction of unregulated treatments. In
addition, direct cellular reprogramming is attracting interest as a
cutting-edge treatment approach because of its advantages such as efficacy and
security.
On
the other hand, an increase in the number of clinical trials related
to advanced therapies is expected to boost the market growth in the coming
years. According to data obtained from the American Society of Gene & Cell
Therapy, in Q1 2022, 32 non-genetically modified cellular therapeutics trials
were initiated, and 69% of these were in the non-oncology arena. Moreover,
according to ClinicalTrials.gov, more than 1800 active cellular therapies are
under clinical trial.
Furthermore,
key companies operating in the market are undertaking several strategic
initiatives such as various agreements, new launches, and expansion to
strengthen their market presence. For instance, in May 2022, the University of
Pennsylvania's personalized cellular therapy was approved for the treatment of
individuals with relapsed or resistant follicular lymphoma.
Moreover,
in April 2021, Bristol Myers Squibb declared that U.S. FDA approved its
Breyanzi (lisocabtagene maraleucel), a novel CAR T treatment for adults with
R/R large B-cell lymphoma. In the pivotal trial for 3L+ LBCL, TRANSCEND NHL
001, Breyanzi showed a 73% overall response rate and a 54% complete response
(CR) rate.
List of Key Players in Cell Therapy Market
- Novartis AG
- Gilead
Sciences, Inc.
- Bristol-Myers
Squibb Company
- Johnson
& Johnson Services, Inc
- JCR
Pharmaceuticals Co., Ltd.
- JW
Therapeutics
- Atara
Biotherapeutics
- Anterogen
Co., Ltd.
- MEDIPOST
- S. BIOMEDICS
Related Press
Release@ Cell Therapy Market Report
Cell Therapy Market Report Highlights
- The
autologous therapy segment dominated the market with the largest revenue
share of 91.22% in 2023, owing to increasing adoption of this therapy type
coupled with lower risk of life-threatening complications
- The allogenic
therapy segment is expected to grow significantly in the coming years
owing to factors such as high pricing and growth in stem cell banking.
Moreover, many companies are preparing to shift their business toward
allogenic cell therapy product development
- Oncology
therapeutic area captured the largest market share in 2023, owing to the
increasing adoption of advanced cell therapies in the treatment of various
types of cancers
- Cell therapy
are also under the investigation for musculoskeletal disorders and has
great potential for market growth
- North
America dominated the market owing to the strong regulatory framework,
presence of bodies like the International Society for Cellular Therapy,
and presence of key operating companies
Cell Therapy Market Report Scope
|
Report Attribute |
Details |
|
Market size value in 2024 |
USD 5.89 billion |
|
Revenue forecast in 2030 |
USD 20.07 billion |
|
Growth rate |
CAGR of 22.66% from 2024 to 2030 |
|
Base year for estimation |
2023 |
|
Historical data |
2018 - 2023 |
|
Forecast period |
2024 - 2030 |
Request For A Free Consultation @ https://www.grandviewresearch.com/request-free-consultation/5491/rfc
Cell Therapy Market Segmentation
Grand
View Research has segmented the global cell therapy market based on therapy
type, therapeutic area, and region.
Cell Therapy Type Outlook (Revenue, USD Million, 2018 -
2030)
- Allogeneic
Therapies
- Stem Cell
Therapies
- Hematopoietic
Stem Cell Therapies
- Mesenchymal
Stem Cell Therapies
- Non-Stem
Cell Therapies
- Keratinocytes
& Fibroblast-based Therapies
- Others
- Autologous
Therapies
- Stem Cell
Therapies
- BM, Blood,
& Umbilical Cord-derived Stem Cells
- Adipose
Derived Cells
- Others
- Non-Stem
Cell Therapies
- T-Cell
Therapies
- CAR T
Cell Therapy
- T Cell
Receptor (TCR)-based
- Others
Cell Therapy Therapeutic Area Outlook (Revenue, USD
Million, 2018 - 2030)
- Oncology
- Cardiovascular
Disease (CVD)
- Musculoskeletal
Disorders
- Dermatology
- Others
Cell Therapy Regional Outlook (Revenue, USD Million, 2018
- 2030)
- North
America
- U.S.
- Canada
- Europe
- UK
- Germany
- Switzerland
- Asia Pacific
- Japan
- China
- India
- South Korea
- Rest of the
World
About Us:
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The company
provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals,
materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment